Skip to content

Oral Acetaminophen for Post-Op Pain Management in Bariatric Surgery Patients

Comparative Efficacy of Two Different Oral Dosage Forms of Acetaminophen for Post-operative Analgesia in Bariatric Surgery Patients

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06658574
Enrollment
65
Registered
2024-10-26
Start date
2024-11-13
Completion date
2026-05-07
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery, Bariatric Surgery (Gastric Bypass), Bariatric Surgery Patients, Perioperative Analgesia, Post Operative Analgesia

Keywords

Acetaminophen, Bariatric, Analgesia, Perioperative, Post Operative

Brief summary

Adult patients with morbid obesity who have had Roux-en-Y gastric bypass (RYGB) or laparoscopic sleeve gastrectomy (LSG) surgery have impaired drug metabolism. There is a paucity of information available on how these patients metabolize acetaminophen post operatively and if drug preparation has any effect on achieving adequate pain control. The surgery may alter the stomach pH, reduce surface area of the stomach, affect transit time, and alter anatomic and physiologic standard absorption of medications. Due to these anatomic and physiologic changes, we seek to understand the potential effects of liquid versus pill formulations of acetaminophen on pain control in this patient population. The purpose of this study is to assess for subjective and objective measures of optimized pain control between formulations of acetaminophen including oral pills and oral liquid.

Detailed description

There is limited information on pharmacokinetics among morbidly obese patients and even less among patients who have undergone metabolic and bariatric surgery (MBS). However, it is known that these patients have altered metabolism due to anatomic and physiologic changes related to body habitus, that are further complicated post MBS. The quadruple aim consists of population health, reduces costs, improved healthcare worker experience and improved patient experience. To provide a comprehensive healthcare approach for this patient population, improved pain management through the utilization of lower cost formulations of acetaminophen can result in improved patient experience through enhanced pain management, avoidance of unnecessary ED visits and/or hospital readmissions. Healthcare worker experience may be improved through less provider and nurse burden from under managed pain, and improved patient outcomes resulting in greater job satisfaction. In 2021, the annual drug overdose death rate in New Jersey is 32.4 per 100,000.3 It is essential that alternatives to opioid medications provide adequate pain control if we are to address this public health crisis. No previous research was identified that evaluates the effectiveness of tablet vs liquid oral acetaminophen despite some evidence of alterations in absorption of tablets among post RYGB or LSG patients. In a small study among severely obese adolescent females, results demonstrated the participants required more than double the amount of IV acetaminophen to achieve equal serum concentrations. Additionally, a small study demonstrated that to achieve near-equivalent pain control post-operatively of colorectal surgery, IV acetaminophen was more effective when administered. Additional studies have demonstrated increased clearance of drugs metabolized by CYP1A2 and CYP2D6 pathways. These pathways are specifically involved in acetaminophen metabolism. The main pathway for acetaminophen metabolism is glucuronidation. Obesity has been associated with increase glucuronide clearance, therefore leaving less acetaminophen available for metabolism by CYP2E1. Furthermore, the anatomic and physiologic changes post-operatively, including a decrease gastrointestinal surface area and length contribute to alternations in drug bioavailability. This evidence leads to the hypothesis that higher dosing of oral acetaminophen is required to achieve adequate pain control when compared to non-obese patients. Based upon previous literature and current understanding of post-operative anatomic and physiologic alterations, there is a lack of evidence to support the preferred formulation of oral acetaminophen in this patient population. Objective: To evaluate the therapeutic effects on pain control of acetaminophen pills vs. acetaminophen liquid on post-operative pain control in patients status post RYGB or LSG. Hypotheses/Research Question(s): H0: There will be no difference in pain control between the liquid and pill formulations of acetaminophen among patients status post RYGB or LSG. H1: The investigators hypothesize that based on post-operative changes, the liquid formulation of acetaminophen will result in improved pain control among patients status post RYGB or LSG. Research Procedures: Prior to initiation of the study, pharmacy, nursing, and medical leadership will be informed of the stratification of acetaminophen formulations based upon surgery day. Patients will be stratified to two arms of the study utilizing the National Cancer Institute's Clinical Trial Randomization Tool. Trial parameters using the asymptotic maximal randomization method, ratio of 1:1, and a participant count of 150 were inputted to create a randomization file. Presently, all patients receive acetaminophen as part of their multi-modal post-operative pain management. The clinical coordinator of the bariatric program on this study will recruit patients during the pre-operative admission process. Consent will occur at the bedside in same day surgery. The clinical coordinator for the bariatric program who is a study team member will be responsible for obtaining patient consent into the study. It is anticipated the consent discussion will be less than 15 minutes per patient. There is no waiting period expected. It is anticipated that equal number of patients in both arms of the study will be obtained. Data Points: Variable will include length of stay (LOS), morphine equivalents, documented pain level, heart rate after cleared from anesthesia, blood pressure after cleared from anesthesia, ED visits within 7 days from discharge, hospital readmissions within 7 days, out of bed/ambulation, time to PO acetaminophen. Demographic data including age, sex, race, weight, height, BMI, co-morbidities. Study Duration: The enrollment period is anticipated to be three months. Total study duration, including data analysis and manuscript writing are anticipated to take two years. Endpoints: Participants may be removed from the study if experiencing inadequate pain control or experiencing elevated glucose levels to ensure pain control and glucose are medically managed as required. Participants will be removed from the study if they experience any allergic reactions to any formulation of acetaminophen to ensure patient safety. Primary outcomes include pain control. Secondary outcomes include LOS and morphine equivalents.

Interventions

DRUGAcetaminophen

Arm 1: Once cleared for oral intake - acetaminophen tablets 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days\' dispensed as unit-dose tablets Arm 2: Once cleared for oral intake - acetaminophen liquid (160 mg/5 mL) 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days; 650 mg = 20.3 mL, dispensed as a unit-dose cup

Sponsors

Rutgers, The State University of New Jersey
Lead SponsorOTHER
Rutgers Robert Wood Johnson Medical School
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 years old or greater who meet patient selection criteria for either primary Roux-en-Y gastric bypass or primary laparoscopic sleeve gastrectomy.

Exclusion criteria

* Patients with a known hypersensitivity or history of intolerance to acetaminophen or any inactive ingredients in either formulation. Patients uncomfortable with or unable to take pills. * Surgical: Duodenal Switch (DS) surgeries, Adjustable Gastric Banding (AGB), surgical revisions, and surgical conversions. * Medical: patients with documented history of chronic and/or current pain syndrome, as evidenced by documentation of ICD-10 code G89.4, patients with documented ICD-10 code F11.90, indication unspecified, uncomplicated opioid use. * Patients of vulnerable populations, as outlined by federal guidelines as children, prisoners, pregnant women, and mentally disabled persons will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Pain ControlFrom date of consent until the date of hospital discharge, assessed up to 3 months.Numeric Pain Score (The scale has a fixed range with 0 representing "no pain" and the upper limit of 10 representing "worst pain possible"). A single numeric pain score is shown as an average of multiple combined time points.

Secondary

MeasureTime frameDescription
Length of Stay (LOS)From date of consent until the date of hospital discharge, assessed up to 3 monthsParticipants' length of hospital stay in days.
Milligrams Morphine Equivalents (MME)From date of consent until the date of hospital discharge, assessed up to 3 monthsThe Milligrams Morphine Equivalents (MME) value represents the potency of an opioid dose relative to morphine. The single MME value is an average across multiple combined time points.
Time From Surgery to Oral IntakeThe time, in hours, from the completion of surgery to the time of oral intake.The amount of time in hours from surgery completion to oral intake documented in the subjects' electronic health record.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORDaniel T Abazia, PharmD

Rutgers University - Ernest Mario School of Pharmacy

Participant flow

Recruitment details

The clinical coordinator of the bariatric surgery program recruited patients during the pre-operative admission process between November 2024 and May 2025. The first participant was enrolled on November 13, 2024, and the last on May 2, 2025.

Pre-assignment details

Of 88 participants screened, 65 met the inclusion criteria and were randomized to treatment.

Baseline characteristics

Characteristic
Age, Continuous41.7 years
STANDARD_DEVIATION 11.5
BMI44.6 kg/m2
STANDARD_DEVIATION 12.2
Comorbidities
Asthma and Other Respiratory Disorders
3 Participants
Comorbidities
Cancer
0 Participants
Comorbidities
Cardiovascular Disease
1 Participants
Comorbidities
Chronic Kidney Disease
2 Participants
Comorbidities
Depression and Anxiety Disorders
4 Participants
Comorbidities
Dyslipidemia
9 Participants
Comorbidities
Gallbladder Disease
0 Participants
Comorbidities
Gastroesophageal Reflux Disease (GERD)
2 Participants
Comorbidities
Hypertension
7 Participants
Comorbidities
Non-alcoholic Fatty Liver Disease
5 Participants
Comorbidities
None
6 Participants
Comorbidities
Obstructive Sleep Apnea
4 Participants
Comorbidities
Osteoarthritis
3 Participants
Comorbidities
Other
6 Participants
Comorbidities
Polycystic Ovary Syndrome (PCOS)
1 Participants
Comorbidities
Type 2 Diabetes Mellitus
6 Participants
Comorbidities
Venous Thromboembolism
0 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
12 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
22 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Height (cm)164.2 centimeters
STANDARD_DEVIATION 7.6
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
7 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
10 Participants
Race (NIH/OMB)
White
26 Participants
Sex: Female, Male
Female
53 Participants
Sex: Female, Male
Male
5 Participants
Weight (kg)123.3 kilograms
STANDARD_DEVIATION 31.2

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 170 / 18
other
Total, other adverse events
0 / 171 / 18
serious
Total, serious adverse events
0 / 170 / 18

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 25, 2026